Our novel platform is based on a proprietary modular design to increase efficacy and safety by increasing delivery to tumors while sparing normal tissues. Cereius carefully considers all of the elements of a targeted radiotherapeutic to guide design parameters specific to each tumor type and disease indication.

  • The conjugation chemistry is the critical link that ensures the radionuclide therapy is safe and precise. Our platform allows site-specific labeling, stabilizes the radionuclide to the ligand while in circulation, reduces exposure to normal tissues, and ensures rapid clearance.
  • The residualizing moiety improves radionuclide retention in tumor cells. Cereius’ proprietary chemistry mitigates cellular catabolism and proteolytic degradation to ensure our radionuclide conjugates are retained within the tumor cell. This results in increased tumor uptake and prolonged therapeutic exposure to the tumor.
  • The targeting ligand has high affinity for the tumor-associated antigen, and our platform can use a sdAb (VHH), a peptide, a small molecule, or a mAb. VHHs are small single-domain antibody fragments that are able to pass through the blood-brain-tumor barrier to reach brain tumors or metastases. Their favorable properties for radiotherapeutic drugs include rapid systemic clearance, good solubility and low immunogenicity.
  • The radionuclide payload is the specific isotope selected to treat the tumor. Our platform uses both β and α emitters. For optimal efficacy, the emission type, energy level, exposure distance, and half-life are selected to specifically target the tumor cells and/or the tumor microenvironment.